Anticancer Aminoferrocene Derivatives Inducing Production of Mitochondrial Reactive Oxygen Species

Area of Science:

• Medicinal Chemistry
• Cancer Therapeutics
• Mitochondrial Biology

Background:

• Cancer cells exhibit elevated reactive oxygen species (ROS) and mitochondrial dysfunction, presenting therapeutic vulnerabilities.
• Simultaneous targeting of these weaknesses is a promising strategy for potent anticancer drug development.
• A key challenge is achieving cancer cell selectivity, minimizing toxicity to normal tissues.

Purpose of the Study:

• To develop novel aminoferrocene (AF)-based derivatives with improved efficacy and reduced toxicity for cancer therapy.
• To investigate an alternative mechanism of action for AF derivatives that enhances cancer cell selectivity.
• To evaluate the in vivo anticancer efficacy of these new AF derivatives.

Main Methods:

• Synthesis and characterization of novel aminoferrocene (AF) derivatives.
• Assessment of chemical stability in the presence of ROS.
• Evaluation of mitochondrial ROS generation in cancer versus normal cells.
• Determination of mitochondrial membrane potential (MMP) changes.
• In vivo testing of anticancer efficacy and toxicity.

Main Results:

• Novel AF derivatives demonstrate chemical stability in ROS-rich environments.
• These compounds selectively induce mitochondrial ROS in cancer cells, sparing normal cells.
• The new AF derivatives exhibit significant in vivo anticancer effects without unspecific toxicity.

Conclusions:

• Unusual AF derivatives offer a promising new therapeutic strategy by selectively targeting cancer cell mitochondria.
• These compounds overcome the limitations of previous AF-based drugs, enabling in vivo application.
• The selective generation of mitochondrial ROS represents a viable approach for developing safer and more effective cancer treatments.